Keratinocyte cancer

Clinical practice guidelines for keratinocyte cancer

From Cancer Guidelines Wiki

NHMRC logo.jpg

The guideline recommendations were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on
7 November 2019 under section 14A of the National Health and Medical Research Council Act 1992. expand arrow

In approving the guideline recommendations, NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years.

NHMRC is satisfied that the guideline recommendations are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.

This publication reflects the views of the authors and not necessarily the views of the Australian Government.

Endorsed by RACGP-lockup endorsed-clinical-guideline for screen.png Endorsement validity: 31 July 2020 – 30 June 2023

download icon Download: Short-form keratinocyte cancer guidelines (recommendations only)
Please also see the following files:

This is a wiki-based guideline. A PDF version of the recommendations in the guideline (short-form guideline), has been made available for download using the link above.



Summary of recommendations

Plain-language summary

1. Epidemiology

2. Prevention of keratinocyte cancer

3. Early detection

4. Clinical features

5. Pathology

6. Prognosis

7. Surgical treatment

8. Radiotherapy

9. Cryotherapy and electrodessication and curettage (EDC)

10. Topical treatments and photodynamic therapy

11. Organ transplantation and other conditions associated with immunosuppression

12. Metastatic disease and systemic therapies

13. Follow-up after treatment for keratinocyte cancer

14. The role of primary care in the prevention and management of keratinocyte cancer

15. Economics of keratinocyte cancer

16. Common concerns raised by patients


Back to top